Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
53 Frontage Road, Suite 220, Hampton, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
AVANT IMMUNOTHERAPEUTICS INC (to 9/29/2008), T CELL SCIENCES INC (to 8/21/1998)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.53K % +84.3%
Debt-to-equity 4.55 % -49.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.4M shares +18.8%
Common Stock, Shares, Outstanding 66.4M shares +18.8%
Entity Public Float 2.4B USD +50%
Common Stock, Value, Issued 66K USD +17.9%
Weighted Average Number of Shares Outstanding, Basic 64.4K shares +32.9%
Weighted Average Number of Shares Outstanding, Diluted 64.4K shares +32.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7.02M USD +1.99%
Research and Development Expense 164M USD +38.6%
General and Administrative Expense 38.5M USD +24.7%
Costs and Expenses 202M USD +25.2%
Operating Income (Loss) -195M USD -26.2%
Earnings Per Share, Basic -2.45 USD/shares +16.1%
Earnings Per Share, Diluted -2.45 USD/shares +16.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.4M USD -18.6%
Marketable Securities, Current 697M USD +79.3%
Assets, Current 747M USD +73.1%
Property, Plant and Equipment, Net 4.35M USD +7.04%
Operating Lease, Right-of-Use Asset 3.9M USD +51.3%
Intangible Assets, Net (Excluding Goodwill) 27.2M USD 0%
Other Assets, Noncurrent 9.75M USD +9009%
Assets 792M USD +70.2%
Accounts Payable, Current 3.27M USD -6.55%
Employee-related Liabilities, Current 11.6M USD +23.7%
Accrued Liabilities, Current 33.8M USD +53.6%
Liabilities, Current 39.5M USD +26.9%
Operating Lease, Liability, Noncurrent 2.36M USD +154%
Other Liabilities, Noncurrent 3.47M USD -21.1%
Liabilities 45.3M USD +24.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.31M USD +0.18%
Retained Earnings (Accumulated Deficit) -1.56B USD -11.3%
Stockholders' Equity Attributable to Parent 747M USD +74.1%
Liabilities and Equity 792M USD +70.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.6M USD -42.2%
Net Cash Provided by (Used in) Financing Activities 436M USD +62740%
Net Cash Provided by (Used in) Investing Activities -315M USD -700%
Common Stock, Shares Authorized 297M shares 0%
Common Stock, Shares, Issued 66.4M shares +18.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 80.3M USD +225%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 28.4M USD -18.6%
Deferred Tax Assets, Valuation Allowance 320M USD -7.95%
Deferred Tax Assets, Gross 325M USD -7.84%
Operating Lease, Liability 3.81M USD +50%
Payments to Acquire Property, Plant, and Equipment 344K USD -41.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -158M USD -13.3%
Lessee, Operating Lease, Liability, to be Paid 4.28M USD +56.4%
Property, Plant and Equipment, Gross 27.8M USD +5.16%
Operating Lease, Liability, Current 1.45M USD -10%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.78M USD +87.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.76M USD -1.51%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 469K USD +141%
Lessee, Operating Lease, Liability, to be Paid, Year Three 742K USD
Deferred Tax Assets, Operating Loss Carryforwards 177M USD -10.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 775K USD +6.75%
Share-based Payment Arrangement, Expense 34.2M USD +43.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%